Artificial Vitreous Body Formulated from Biomaterials Obtained from Algae A collaborative effort between Korean scientists has resulted in the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae. Weiterlesen 208
Optic Nerve Damage: A Path to Regeneration Damage to the optic nerve can lead to irreversible blindness. A newly investigated regeneration factor could change that, researchers of the University of Connecticut (UConn) report in the May 2024 issue of Experimental Neurology. This opens up a completely new field of research – in glaucoma or other types of nerve damage. Weiterlesen 263
AMD: Protein FHR-4 no promising therapeutic target? Over the past decade, researchers at the John A. Moran Eye Center’s Sharon Eccles Steele Center for Translational Medicine (SCTM) have clarified the genetics of AMD, refined the clinical understanding of its natural course of progression, and developed potential new treatments. Publishing in the prestigious journal Nature Communications, the SCTM’s latest AMD research points the field away from a liver-produced protein others had identified as a promising therapeutic target. Weiterlesen 188
Scientists discover a worm with enormous and surprisingly sharp-seeing eyes The Mediterranean marine worm Vanadis can be found around the Italian island of Ponza. Its eyesight rivals that of rodents such as mice and rats. Its eyes weigh about 20 times more than the rest of its head. The worms can see UV light and focus on relatively small objects, tracking them as they move. Weiterlesen 397
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in retinitis pigmentosa patients / VG901, using ViGeneron’s proprietary next-generation technology platform vgAAV, is administered intravitreally (IVT), offering enhanced ease of delivery, broader vector distribution, and mitigating the risk of retinal damage linked with subretinal administration / VG901 granted Orphan Drug Designation by FDA. Weiterlesen 440
Geographic Atrophy: Aviceda Therapeutics Announces Formation of European Clinical Advisory Board The European Clinical Advisory Board (CAB) is made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Weiterlesen 405
National Eye Institute: Study points to ‘ground zero’ for AMD development Integrative omics approach finds 87 genes where aging, diet, lifestyle and smoking may take toll by affecting epigenome. Weiterlesen 464
Researchers uncover the microbial secrets of dry eye Insights into the ocular microbiome could have implications beyond eye health. Weiterlesen 499
FDA Approval For Clobetasol Propionate Eye Drop for Post-Operative Inflammation And Pain The first new steroid to the ophthalmic sector in more than a decade: Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics (United States) announced that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. Weiterlesen 544
AI has perfect detection rate for severe cases of retinopathy of prematurity The technology could expand global treatment before condition can permanently damage vision. Weiterlesen 663
Novel Protocol to Rapidly Diagnose and Treat Central Retinal Artery Occlusion Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai (NYEE) have created a novel protocol to rapidly diagnose eye stroke and expedite care to prevent irreversible vision loss. Weiterlesen 399
Augeninnendruck-Monitoring mit dem iCare HOME2 Tonometer – Fachgespräch mit Glaukomexpertin Dr. Barbara Wirostko Der Augeninnendruck gilt als wichtigster Risiko- und einziger therapeutisch beeinflussbarer Faktor bei einer Glaukomerkrankung. Doch er ist Schwankungen unterworfen. Auch diese nur vorübergehenden Druckerhöhungen können zu einer Sehnervenschädigung führen. Aus diesem Grunde ist es so wichtig, den Augeninnendruck im Verlauf zu überprüfen – etwa mit dem iCare HOME2. Mehr dazu im neuen EYEFOX Fachgespräch. Weiterlesen 676
Neu in der EYEFOX Mediathek: Ab-interno Kanaloplastik mit dem iTrack™ Advance – Chirurgische Tipps und Tricks Dr. Karl Mercieca (Universitätsklinikum Bonn) und Dr. Karsten Klabe (Breyer, Kaymak & Klabe Augenchirurgie, Düsseldorf) teilen ihre chirurgischen Tipps und Tricks für eine erfogreiche Kanaloplastik mit dem neuen iTrack™ Advance Kanaloplastikgerät. Weiterlesen 611
Neu in der EYEFOX Mediathek: Ab-interno Kanaloplastik – Ein Fachgespräch mit Dr. Karl Mercieca Der iTrack™ Advance Kanaloplastik-Mikrokatheter erleichtert den Zugang ins vordere Augensegment unter kontinuierlicher Sichtkontrolle bei chirurgischen Eingriffen zur Reduktion des Augeninnendrucks bei Patienten mit Offenwinkelglaukom. Weiterlesen 723